Alto Neuroscience, Inc. (ANRO NYSE) stock market data APIs
$2.2725
0.09(4%)
as of April 22, 2025
Alto Neuroscience, Inc. Financial Data Overview
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Prev. Close
2.2725
Open
2.3666
High
2.3666
Low
2.1569
52 wk Range
1.6-17.55
Market Cap
61 183 K
Shares Outstanding
27 072 K
EPS
-0.52
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alto Neuroscience, Inc. data using free add-ons & libraries
Get Alto Neuroscience, Inc. Fundamental Data
Alto Neuroscience, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -68 108 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-21
- EPS/Forecast: -0.65
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alto Neuroscience, Inc. News
New
15 Healthiest Countries in Asia
In this article, we will be taking a look at the 15 Healthiest Countries in Asia. You can skip our detailed analysis on the health market and directly head to the 5 Healthiest Countries in Asia. Grow...
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
One of the best ways to be successful in the stock market is by identifying under-the-radar stocks before they blow up. All of today’s biggest and most valuable companies were once entirely unknown....
Insiders are Piling into These 10 Healthcare Stocks in 2024
In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our articleInsiders are Piling into These 5 Hea...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
